| abstract |
The present invention relates to N 4 -acyl-2 ', 3'-dideoxy-5-fluorocytidine or N 4 -acyl-2', 3'-didehydro--2 ', 3'-dideoxy-5- Viral infections, particularly human immunodeficiency virus (HIV) and hepatitis B virus, in human patients or other animal hosts, including administering fluorocytidine and its pharmaceutically acceptable salts, prodrugs and other derivatives thereof ( HBV) methods and compositions for treating or preventing infections. |